15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Insmed Inc, 20 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $160.00 to $245.00, a moderate spread. The average target of $208.00 sits 100% above the current $104.11. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 19 to 20 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.61 next quarter toward $0.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Strong Buy
Strong Buy00%
Buy20100%
Hold00%
Sell00%
Strong Sell00%
Based on 20 analysts giving stock ratings to Insmed Inc.
As of Jul, 20 of 20 firms rate INSM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
INSM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.61
Range $-1.14 – $-0.30 · 16 analysts · -65% YoY
Next period, 16 analysts expect Insmed Inc to earn $-0.61 a share (range $-1.14 – $-0.30), versus $-1.75 a year earlier. Full-year consensus is $-2.59, growing to $0.13 the year after.
REVENUE · NEXT QUARTER
$465.8M
Range $438.9M – $520.0M · 16 analysts · +227% YoY
Revenue is expected to reach $465.8M (range $438.9M – $520.0M), +227.2% year-over-year. Full-year consensus is $1.7B, rising to $2.8B next year.
Top analysts covering Insmed Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INSM.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$220.00+111.3% to target
Overall win rate
46%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #64
Buy
$179.00+71.9% to target
Overall win rate
52%
+ Follow
#3
Leonid Timashev
RBC Capital · Rank #69
Buy
$195.00+87.3% to target
Overall win rate
42%
+ Follow
#4
Matthew Harrison
Morgan Stanley · Rank #243
Buy
$212.00+103.6% to target
Overall win rate
44%
+ Follow
#5
Benjamin Burnett
Wells Fargo
Buy
$161.00+54.6% to target
Coverage
—
+ Follow
INSM stock forecast FAQ
What is INSM's average 12-month price target?+
The 18 analysts with a live target average $208.00 for Insmed Inc over the next 12 months, ranging from a $245.00 high to a $160.00 low.
Is INSM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 20 analyst ratings, 20 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for INSM?+
The Street-high target is $245.00 (HC Wainwright & Co.), and the Street-low is $160.00 (Evercore ISI Group). The average of all 18 active targets is $208.00.
How many Wall Street analysts cover INSM?+
20 analysts have an active rating on Insmed Inc, and 18 firms carry a live 12-month price target.
Who is the most accurate analyst covering INSM?+
Among analysts who currently cover INSM, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $220.00 target.
What is Insmed Inc's projected EPS for next quarter?+
The consensus estimate is $-0.61 per share (range $-1.14 – $-0.30) across 16 analysts. Full-year EPS is projected at $-2.59, rising to $0.13 the following year.
How much revenue is Insmed Inc expected to report next quarter?+
Consensus revenue is $465.8M (range $438.9M – $520.0M). Full-year revenue is projected at $1.7B, growing to $2.8B next year.
Have analysts been upgrading or downgrading INSM lately?+
As of Jul, 20 of 20 firms rate INSM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INSM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
